«

»

Oct 30

Blocked the formation of new vascular networks and reorganizes existing networks.

Further investigations have shown that. These effects DAL produced by reduction of the activity of Rac1, a protein important known cellular adhesion, and cytoskeletal organization This work is the first anti-vascular anti-vascular effects of DAL and its target Rac1, and close our data suggest that Rac1 DAL promotes degradation, says Rakesh Jain, Director of the Steele Lab and senior author of of the study. DAL has the potential to treat many types of cancer and other diseases, the improvement characterized by abnormal blood vessels. Jain is the Cook Professor of Radiation Oncology and Garkavtsev is an assistant professor of radiation oncology at Harvard Medical School..

One of the two compounds were identified from this process dehydro – alpha-lapachone , avellanedae of Tabebuia, a tree from Argentina and Brazil. Since DAL has structural similarities with other agents with anti-tumor activity and does not appear to be toxic, it was selected for further investigation. The researchers first showed that DAL administration interfered with blood vessel formation in the zebrafish, both during embryonic development and wound healing. They then found that it is the reduced vascular density of tumors implanted in mice and with daily treatment significantly reduced tumor growth with no signs of toxicity.

In their search for drugs that of blood vessels in of blood vessels in different Garkavtsev Garkavtsev and his colleagues involved in the ways with the liability of line line blood vessels of the outer vessel wall.Stargardt disease macular dystrophy, dry AMD can and other types of atrophy of related Macular Degeneration have is generally impossible for treated Those common forms of blindness much safe and effective treatments Lanza said:.. The scientists reported their findings in 13th March 2008 issue of the magazine Neuron, of Cell Press.

Two patients were treated with a RPE cells from human embryonic stem cells of derived in two Phase 1/2 clinical studies in dry age-related macular degeneration and the Stargardt disease macular dystrophy has announced Advanced Cell Technology Inc.